The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) and fibrotic nonspecific interstitial pneumonitis are progressive interstitial lung diseases (ILDs) with limited treatment options and poor survival. However, the rate of disease progression is variable, implying there may be different endotypes of disease. We hypothesised that immunophenotyping biopsies from ILD patients might reveal distinct endotypes of progressive fibrotic disease, which may facilitate stratification when undertaking clinical trials of novel therapies for IPF. 43 paraffin-embedded, formalin-fixed lung tissue sections were immunostained for five molecules implicated in the pathogenesis of the fibrosis: α-smooth muscle actin (αSMA), αvβ6 integrin, pro-surfactant protein C (SP-C), hepatocyte growth factor (HGF) and tenascin-C (TenC). Levels of immunostaining and numbers of fibroblastic foci were quantified using operator-dependent and -independent methods. The relationship of all these markers to overall survival was analysed. Staining revealed high levels of αSMA, αvβ6 integrin, pro-SP-C, HGF and TenC, and fibroblastic foci. Immunostaining varied across samples for all molecules but only the extent of αvβ6 integrin immunostaining was associated with increased mortality. There was no association with the other markers measured. Our data suggest high levels of αvβ6 integrin may identify a specific endotype of progressive fibrotic lung disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“αvβ6 levels are increased in lung tissue from IPF patients and correlate with poorer prognostic outcomes, so that this integrin might also hold prognostic value (Saini et al., 2015).”
From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Saini et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,651
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Histopathologic Variability in Usual and Nonspecific Interstitial Pneumonias
FLAHERTY, K. R., Travis, W. D., Colby, T. V., Toews, G. B., Kazerooni, E. A., Gross, B. H., Jain, A. K., Strawderman, R. L., Flint, A., Lynch, J. P., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2103074 · Cited by 666
King, T. E., Schwarz, M. I., Brown, K. M., Tooze, J. A., Colby, T. V., Waldron, J. A., Flint, A., Thurlbeck, W. M., & Cherniack, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.6.2001056 · Cited by 629
MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E., Lindell, K. O., Cisneros, J., MacDonald, S. D., Pardo, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050093 · Cited by 582
Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK
Gribbin, J., Hubbard, R., Jeune, I. L., Smith, C. J. P., West, J., & Tata, L. J. (2006) · Thorax · doi:10.1136/thx.2006.062836 · Cited by 574
Molecular Targets in Pulmonary Fibrosis
Scotton, C. J., & Chambers, R. C. (2007) · CHEST Journal · doi:10.1378/chest.06-2568 · Cited by 538
The rising incidence of idiopathic pulmonary fibrosis in the UK
Navaratnam, V. V., Fleming, K. M., West, J., Smith, C. J. P., Jenkins, G. R., Fogarty, A., & Hubbard, R. (2011) · Thorax · doi:10.1136/thx.2010.148031 · Cited by 484
Self-citationPartial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-805oc · Cited by 420
Self-citation
Cited by
Sorted by citations
Emerging therapeutic opportunities for integrin inhibitors
Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, G. R., & Hatley, R. J. D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00284-4 · Cited by 558
Self-citationJenkins, G. R., Moore, B. B., Chambers, R. C., Eickelberg, O., Königshoff, M., Kolb, M. R. J., Laurent, G. J., Nanthakumar, C. B., Olman, M. A., Pardo, A., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0096st · Cited by 460
Self-citationMaher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., Flynn, A., Molyneaux, P. L., Braybrooke, R., Divyateja, H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30430-7 · Cited by 271
Self-citationThe therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N. C., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 276
Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history
Sgalla, G., Biffi, A., & Richeldi, L. (2015) · Respirology · doi:10.1111/resp.12683 · Cited by 178
Metadata
- Authors
- Saini, G., Porte, J., Weinreb, P. H., Violette, S. M., Wallace, W. A., McKeever, T. M., & Jenkins, G.
- Affiliations
- University of Nottingham (GB)
- Biogen (United States) (US)
- University of Edinburgh (GB)
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2015-03-05
- Volume
- 46
- Issue
- 2
- Pages
- 486-494
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2113575939
- Cited by
- 106
- References
- 38
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 16 · 2022: 7 · 2021: 11 · 2020: 13 · 2019: 5 · 2018: 11 · 2017: 9 · 2016: 9 · 2015: 3
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (acceptedVersion, other-oa)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- Nottingham ePrints (University of Nottingham) (submittedVersion)
- Funders
- Medical Research Council (MICA grant G0901226)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- integrin αvβ6, idiopathic pulmonary fibrosis, interstitial lung disease, prognostic factors, disease endotypes, overall survival, fibroblastic foci, alpha-smooth muscle actin, hepatocyte growth factor, tenascin-C, pulmonary fibrosis
- MeSH terms
- Adult, Aged, Antigens, Neoplasm, Biopsy, Female, Humans, Lung, Male, Middle Aged, Prognosis, Biomarkers, Integrins, Lung Diseases, Interstitial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
